EVE133

EVE133 is an investigational intravaginal ring being developed by Evestra for the treatment of overactive bladder (OAB). The product utilizes Evestra's proprietary vaginal ring technology platform to facilitate the local, sustained delivery of a hormone directly to the urogenital tissues. While the specific active pharmaceutical ingredient and its molecular target have not been publicly disclosed, the therapy is designed to address the symptoms of OAB—such as urinary urgency and frequency—by providing localized treatment that may minimize the systemic side effects often associated with oral OAB medications. EVE133 represents a part of Evestra's broader focus on innovative women's healthcare products leveraging specialized drug delivery systems.